Priority review sets up Feb verdict on Sanofi, Sobi haemophi...

The FDA will carry out a speedy review of Sanofi and Sobi's once-weekly haemophilia A treatment efanesoctocog alfa (Bivv001), with a decision now

Roctavian okay sets up another gene therapy test for Europe

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe

Novo Nordisk's concizumab hits mark in haemophilia, but dosi...

Novo Nordisk has reported phase 3 results with its concizumab drug for haemophilia A or B, showing efficacy in the prevention of bleeding events that will support regulatory filings startin

Sanofi trumpets data with haemophilia treatment duo at ISTH

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at th

Sanofi/Alnylam's haemophilia drug hits another safety speed-...

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after the company voluntarily placed its late-stage trials of fitusiran on hold b

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...